title: Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
abstract: Respiratory viruses infections caused by influenza viruses, human parainfluenza virus (hPIV), respiratory syncytial virus (RSV) and coronaviruses are an eminent threat for public health. Currently, there are no licensed vaccines available for hPIV, RSV and coronaviruses, and the available seasonal influenza vaccines have considerable limitations. With regard to pandemic preparedness, it is important that procedures are in place to respond rapidly and produce tailor made vaccines against these respiratory viruses on short notice. Moreover, especially for influenza there is great need for the development of a universal vaccine that induces broad protective immunity against influenza viruses of various subtypes. Modified Vaccinia Virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform. MVA can encode one or more foreign antigens and thus functions as a multivalent vaccine. The vector can be used at biosafety level 1, has intrinsic adjuvant capacities and induces humoral and cellular immune responses. However, there are some practical and regulatory issues that need to be addressed in order to develop MVA-based vaccines on short notice at the verge of a pandemic. In this review, we discuss promising novel influenza virus vaccine targets and the use of MVA for vaccine development against various respiratory viruses.
authors.affiliation: Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. a.altenburg@erasmusmc.nl.
authors.forename: Arwen F
authors.initials: AF
authors.lastname: Altenburg
authors.affiliation: Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. j.kreijtz@erasmusmc.nl.
authors.forename: Joost H C M
authors.initials: JH
authors.lastname: Kreijtz
authors.affiliation: Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. r.d.devries@erasmusmc.nl.
authors.forename: Rory D
authors.initials: RD
authors.lastname: de Vries
authors.affiliation: Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. fei.song@micro.vetmed.uni-muenchen.de.
authors.forename: Fei
authors.initials: F
authors.lastname: Song
authors.affiliation: Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. robert.fux@micro.vetmed.uni-muenchen.de.
authors.forename: Robert
authors.initials: R
authors.lastname: Fux
authors.affiliation: Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. g.rimmelzwaan@erasmusmc.nl.
authors.forename: Guus F
authors.initials: GF
authors.lastname: Rimmelzwaan
authors.affiliation: Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. gerd.sutter@lmu.de.
authors.forename: Gerd
authors.initials: G
authors.lastname: Sutter
authors.affiliation: Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. asisa.volz@micro.vetmed.uni-muenchen.de.
authors.forename: Asisa
authors.initials: A
authors.lastname: Volz
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D056738:Cross Protection; D005822:Genetic Vectors; D006801:Humans; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D009975:Orthomyxoviridae / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D018108:Respirovirus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014765:Viral Vaccines